Literature DB >> 11934306

Hyperosmotic stress and elevated pCO2 alter monoclonal antibody charge distribution and monosaccharide content.

Albert E Schmelzer1, William M Miller.   

Abstract

Medium osmolality increases with pCO2 at constant pH. Elevated pCO2 and osmolality inhibit hybridoma growth to similar extents in both serum-containing and serum-free media. The combination of osmolality and elevated pCO2 synergizes to negatively impact cell growth. IgG2a glycosylation by hybridoma cells was evaluated under elevated pCO2 (to 250 mmHg pCO2) and/or osmolality (to 476 mOsm/kg). IgG2a site occupancy did not change significantly under any of the conditions studied, which is consistent with the robust glycosylation of other antibodies produced under various environmental stresses. However, changes were observed in the IgG2a charge distribution. Changes in the isoelectric point (pI) were greater under hyperosmotic stress, increasing by 0.32 and 0.41 pH units at 435 mOsm/kg in serum-containing and serum-free medium, respectively. Hyperosmotic stress also resulted in a concomitant increase in the heterogeneity of the charge distribution. The mean pI in serum-containing medium decreased by 0.16 pH units at 250 mmHg pCO2 when osmolality was controlled at 320 mOsm/kg but increased by 0.20 pH units when the osmolality increased with pCO2 (195 mmHg pCO2-435 mOsm/kg). In serum-free medium, elevated pCO2 did not alter pI, regardless of medium osmolality. In contrast to elevated osmolality at control pCO2, elevated pCO2 did not significantly alter the IgG2a charge heterogeneity under any of the conditions studied. The IgG2a was not sialylated, so sialylation changes were not responsible for changes in the charge distribution. IgG2a galactose content decreased with elevated osmolality, as a result of either elevated NaHCO3 or NaCl. However, when osmolality was controlled at elevated pCO2, the galactose content tended to increase. The mannose content decreased with increasing stress, while the fucose content remained relatively unchanged. It is likely that the observed increases in the pI of murine IgG2a were due to increased organellar pH, which is reflected by increased specific beta-galactosidase activity in the supernatant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934306     DOI: 10.1021/bp010187d

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  7 in total

1.  Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity.

Authors:  Yoshinobu Konno; Yuki Kobayashi; Ken Takahashi; Eiji Takahashi; Shinji Sakae; Masako Wakitani; Kazuya Yamano; Toshiyuki Suzawa; Keiichi Yano; Toshio Ohta; Masamichi Koike; Kaori Wakamatsu; Shinji Hosoi
Journal:  Cytotechnology       Date:  2011-08-27       Impact factor: 2.058

Review 2.  [Permissive and non-permissive hypercapnia: mechanisms of action and consequences of high carbon dioxide levels].

Authors:  Arturo Briva; Emilia Lecuona; Jacob I Sznajder
Journal:  Arch Bronconeumol       Date:  2010-03-19       Impact factor: 4.872

Review 3.  Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components

Authors:  Fatemeh Torkashvand; Behrouz Vaziri
Journal:  Iran Biomed J       Date:  2017-04-20

4.  Impact of mammalian cell culture conditions on monoclonal antibody charge heterogeneity: an accessory monitoring tool for process development.

Authors:  Bernhard Sissolak; Nico Lingg; Wolfgang Sommeregger; Gerald Striedner; Karola Vorauer-Uhl
Journal:  J Ind Microbiol Biotechnol       Date:  2019-06-07       Impact factor: 3.346

5.  Lectin bio-layer interferometry for assessing product quality of Fc- glycosylated immunoglobulin G.

Authors:  Jakob Wallner; Bernhard Sissolak; Wolfgang Sommeregger; Nico Lingg; Gerald Striedner; Karola Vorauer-Uhl
Journal:  Biotechnol Prog       Date:  2019-06-22

6.  A novel approach to noninvasive monitoring of dissolved carbon dioxide in small-scale cell culture processes.

Authors:  Vida Rahmatnejad; Michael Tolosa; Xudong Ge; Govind Rao
Journal:  Front Bioeng Biotechnol       Date:  2022-09-06

7.  Clinical considerations for biosimilar antibodies.

Authors:  Håkan Mellstedt
Journal:  EJC Suppl       Date:  2013-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.